- 1 Title
- 2 The Causal Association between Gut Microbiota and Pancreatic Cancer: A Two-sample
- 3 Mendelian Randomization Analysis in European and East Asian Populations
- 4 Authors
- 5 Yinbo Xiao<sup>1#</sup>, Xiang Li<sup>2#</sup>, Long Zou<sup>1</sup>, Daniel M. Wall<sup>2</sup>, Zhiyong Liang<sup>1</sup>
- 6 <sup>1</sup>Department of Pathology, State Key Laboratory of Complex Severe and Rare Diseases,
- 7 Molecular Pathology Research Centre, Peking Union Medical College Hospital, Chinese
- 8 Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- 9 <sup>2</sup>School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, Sir
- 10 Graeme Davies Building, University of Glasgow, Glasgow G12 8TA, United Kingdom
- 11 # These authors contributed to the work equally.
- 12 **Corresponding author**: Zhiyong Liang (e-mail: liangzy@pumch.cn)
- 14 Financial support: This study was supported by funding from National Natural Science
- 15 Foundation of China (No. 82072749).
- 16 Author contributions: Yinbo Xiao and Xiang Li: conception and design of the study and
- 17 original draft preparation. Long Zou: literature search and original draft preparation. Zhiyong
- 18 Liang and Daniel M. Wall: revision and approval of the manuscript. All authors approved the
- 19 final version of the article.
- 20 **Declaration of conflict of interest**: The authors declare that they have no conflicts of
- 21 interest.

- 22 **Ethics statement:** Ethical review and approval were not required for this study because this
- 23 study was based on public databases.

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

Abstract Background and Aim: Alterations in the gut microbiota strongly correlate with the onset of pancreatic cancer (PC). However, any causal relationship between gut microbiota alterations and PC risk remains unknown. Methods: We comprehensively investigated PC-related microorganisms in European and East Asian populations through the application of Mendelian randomization (MR). The PC genome-wide association study (GWAS) databases for European and East Asian individuals were acquired from the UK and Japanese Biobanks, respectively. Primary analytical methods, including the inverse variance weighted (IVW) method, weighted median, Maximum likelihood method and MR PRESSO, were employed to estimate the potential causal association between gut microbiota and PC. Additionally, we performed sensitivity analysis and reverse MR analysis. Results: By IVW method, overall 17 bacterial taxa were identified with potential causal correlations to PC. The PC-associated gut microbiota signatures varied across different populations. Among these, 4 specific taxa exhibited potential causality with PC, with statistical significance in all four MR methods. Specifically, the *Alcaligenaceae* family was identified as protective, while genus Sutterella, order Bacilliales and genus Enterohabdus were associated with increased risk of PC. Among the European population within the UK biobank, the Alcaligenaceae family, genus Sutterella, and order Bacillales were connected to PC, while genus Enterohabdus was linked to PC in the Japanese cohort. Conclusion: Our study implicates certain members of the gut microbiota in PC onset based on genetics. Further investigations of the gut-pancreas axis may lead to the development of novel microbiome targeted prevention strategies for PC. **Keywords** pancreatic cancer, gut microbiota, Mendelian randomization analysis.

50 Introduction 51 Pancreatic cancer (PC), especially pancreatic ductal adenocarcinoma, is one of the most 52 lethal malignancies worldwide [1]. With an estimated 49,830 deaths attributed to PC in 53 2022, it remains the fourth most common cause of cancer-related deaths in the US [2]. 54 Moreover, it is predicted to become the second leading cause of cancer-related deaths by 55 2030 in the US [3]. The incidence and mortality rates of PC are continuously increasing year 56 by year, unfortunately with minimal progress in the overall survival rate [4]. Thus, it is urgent 57 to gain a deeper understanding of the biological mechanisms underlying PC carcinogenesis, 58 potentially leading to novel treatment and management strategies for PC to reduce such 59 public health burden. 60 The role of the gut microbiome in PC development, known as the microbiome-pancreas axis, has gained significant attention [5]. Microbiota from the gut can enter the pancreas via the 61 62 circulatory system or pancreatic duct [6, 7]. Numerous research studies have revealed that 63 gut microbiota alterations are involved in the advent of PC [8-11], even though the 64 underlying molecular mechanisms remain unclear. Moreover, some epidemiological studies have demonstrated that the risk of PC is positively correlated to the abundance of some gut 65 66 microbiota, such as Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis and 67 Helicobacter Pylori [10, 12, 13]. These studies indicated that the gut microbiota could serve 68 as biomarkers for PC in clinical practice and be utilized for early detection of PC and prognosis of outcomes. However, a causal role for the gut microbiota in PC has not been 69 70 established, due to confounding factors and the potential for reverse causality [14-16]. 71 Mendelian randomization (MR) is an epidemiological method whereby genetic variants are 72 employed as instrumental variables (IVs) to determine the causal relationship between risk 73 factors and disease outcomes [17, 18]. The use of genetic variants is advantageous as they 74 are randomly distributed during conception, reducing the impacts of confounding factors 75 and eliminating reverse causation bias. Consequently, MR analysis is less susceptible to the 76 influence of environmental and self-adopted confounding factors [19]. In this study, MR 77 offers a valuable approach to estimate the causal link between the gut microbiota and the 78 risk of PC. 79 Using MR analysis, previous studies have identified the causal relationships between the gut 80 microbiome and several cancers, including liver cancer [20], colorectal cancer [21], and lung

cancer [22]. However, any causal association between the gut microbiota and PC is still

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

unclear. Furthermore, most MR studies are largely derived from European populations, while there is a limited number of studies employing MR analysis in non-European cohorts. Here, we performed a two-sample MR analysis to evaluate the association between the gut microbiome and PC risk among both European and East Asian populations. Our study can enhance the theoretical basis for the gut-pancreas axis leading to novel insights into the predictors of PC as well as potential treatment targets. Methods **Exposure data** Genetic variants related to the gut microbiota composition were acquired from the largescale genome-wide association study (GWAS) [23]. The gut microbiota was profiled by targeting three variable regions V1-V2, V3-V4 and V4 of the 16S rRNA gene. The metaanalysis encompassed a total of 18,340 participants derived from 24 cohorts originating from several countries including the United States, Canada, Israel, South Korea, Germany, the United Kingdom. Following adjustment for age, gender, technical covariates, and genetic principal components, the quantitative microbiome trait loci analysis yielded a total of 211 GWAS summary statistics associated with microbial taxa. These were 9 phyla, 16 classes, 20 orders, 35 families (including 3 families with unknown classification), and 131 genera (with 12 genera of unknown classification). The summary data is available for download from https://mibiogen.gcc.rug.nl/. **Outcome data** The UK Biobank and the Japan Biobank were used to investigate the causal relationship between the microbiome and pancreatic cancer. The cohort data from the UK Biobank of PC involved 589 PC cases and 393372 healthy control. Summary analysis statistics are available from the Lee Lab (https://www.leelabsg.org/resources). The summary GWAS data of the Japan Biobank included 442 PC cases and 195745 healthy controls. Data was acquired from the IEU Open GWAS project (https://gwas.mrcieu.ac.uk/datasets/). **Assumptions** The schematic representation of the investigation is depicted in **Figure 1**. In this study, the gut microbiota was considered as the exposure, while PC was regarded as the outcome. Three fundamental assumptions were necessary for a proper MR study. First, the genetic variants designated as IVs were strongly related to the exposure. Second, the relationships

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

between genetic variations and outcomes were not influenced by any other confounding variables. Third, it should be noted that the impact of genetic variations on the outcome was only mediated by their influence on the specific exposure under investigation. It meant that no occurrence of horizontal pleiotropy was shown between the genetic variants and the outcome. Instrumental variable selection Excluding 15 unknown classifications, a total of 196 taxa at five different levels (phylum, class, order, family, and genera) were conducted as the exposure datasets. Potential IVs were selected by single nucleotide polymorphisms (SNPs) with a less stringent significant association at a threshold of  $P < 1.0 \times 10^{-5}$ . The approach was employed to augment the pool of SNPs accessible for conducting sensitivity tests, as demonstrated in prior studies [23, 24]. Independent SNPs were clumped as IVs based on linkage disequilibrium (LD) R<sup>2</sup> < 0.01 and clumping distance equal to 10,000 kb. The strengths of the IVs were estimated by F statistics. Specifically, the extent to which the IVs accounted for variance was computed for each exposure. F statistics were calculated with the following equation,  $r^2 * (N - 1 - k) / [(1 - k) / (N - 1 - k)]$ r<sup>2</sup>)\* k], where r<sup>2</sup> was the variance explained, N was the sample size and k was the number of IVs [25]. To calculate F statistics for independent IVs, k was equal to 1. Finally, independent IVs with F-statistics below 10 were deemed to be weak IVs and therefore were eliminated from the analysis. To identify whether selective IVs were associated with confounders, PhenoScanner was applied to exclude IVs significantly associated ( $P < 5 \times 10^{-8}$ ) with potential confounders (i.e., obesity, smoking, diet, or other diseases). Mendelian randomization analysis MR analysis was conducted in R using TwoSampleMR package version 0.5.7 [26]. Selected IVs from different gut microbiota taxa were combined with the PC outcome SNPs dataset. To ensure the effects of SNPs on the exposure corresponding to the same allele as the effects on the outcome, shared SNPs were harmonised across exposure and outcome databases. At least 3 shared SNPs available between exposure and outcome were then selected for further MR analysis. To evaluate causal estimates between the gut microbiota and the risk of PC, MR causality tests were performed using four different approaches: inverse-variance-weighted (IVW) method, weighted median, maximum-likelihood method and MR-PRESSO [27]. In particular, the IV method of estimation was fundamentally a meta-analysis technique which was operated under the assumption that IVs had a causal impact on the outcome solely

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

through the exposure, rather than through any other pathways [28]. The weighted median estimator provided valid estimations of causal effect when no more than 50% of the information was from invalid instruments. MR PRESSO was employed to estimate the pleiotropy, which corrected the estimation by eliminating outliers from the IVW model. Therefore, the presence of a causal relationship was determined when a statistically significant P value (P < 0.05) was obtained from any of the four methods used in the MR analysis. Sensitivity analysis After MR analysis, sensitivity analysis was performed to evaluate potential heterogeneity and pleiotropy. The Cochran's Q statistics were employed for heterogeneity analysis. When the p-value of Q statistics was less than 0.05, it might be interpreted as evidence of heterogeneity. MR-Egger intercept, as well as MR-PRESSO test, were conducted to monitor the potential horizontal pleiotropy. An insignificant P value (P > 0.05) in the MR-Egger intercept test was defined as the absence of pleiotropy. The MR-PRESSO test was also conducted to examine pleiotropic biases and address the pleiotropic effects by eliminating outliers. MR analysis report was not supported by the MR PRESSO outliers-adjusted test (P > 0.05) representing substantial pleiotropy. In addition, leave-one-out analysis was performed to determine if the causal estimates were biased by any one single SNP. Leaveone-out analysis was able to identify one SNP driving the signal when all, but one leave-oneout configuration had P < 0.05. **Reverse MR analysis** To determine whether PC had any causal impact on the identified significant microbiota, a reverse MR analysis was conducted (PC as the exposure and the identified significant gut microbiota as the outcome), by using SNPs that were strongly associated with PC as IVs (p < 5x10<sup>-6</sup>). Causal tests based on the MR framework were then conducted, following the same methodology as described in the section "Mendelian randomization analysis". To eliminate intricate causality possibility, we also excluded any results in which the P-value of reverse MR was less than 0.05.

173 Results 174 Selection of instrumental variables 175 IVs were sorted by  $p < 1x10^{-6}$ . After excluding unknown bacterial genera or ones containing 176 less than three IVs, a total of 119 bacterial genera were used as exposure datasets. The Fstatistics of IVs were more than 10, suggesting that there was no evidence of weak 177 178 instrument bias. Details about the selected IVs for 119 genera were shown in 179 **Supplementary Table S1.** Association of specific members of the gut microbiota with PC 180 181 In the MR analysis, 17 bacterial genera were genetically predicted associated with the risk of 182 PC in the IVW method of MR analysis. Specifically, there were 11 genera (class Bacyeroidia, family Alcaligenaceae, family Veillonellacease, genus Bilophila, genus Eggerthella, genus 183 184 LachnospiraceaeUCG004, genus LachnospiraceaeUCG010, genus Parasutterella, genus 185 Sutterella, order Bacillales, and order Bacteroidales) in European ancestry from the UK 186 Biobank (**Table 1**), while 6 genera (class *Atinobacteria*, family *Christensenellaceae*, genus 187 Ruminococcusgnavus group, genus Enterohabdus, genus Ruminococcus1, order 188 Burkholderiales) were identified in East Asian ancestry from the Japan Biobank (Table 2). The 189 scatter plots of IV potential effects on PC versus gut microbiota in the European and East 190 Asian populations were demonstrated in **Supplementary Figure S1 and S2**, respectively. In 191 order to identify the strongest evidence of significant risk factors between any microbial taxa 192 and PC, 17 significant bacterial genera were valued in 4 different MR analysis methods (IVW, 193 weighted median, Maximum likelihood, and MR PRESSO). The most significant risk factors 194 were required to achieve a p-value below 0.05 in all four distinct techniques of MR analysis. 195 Hence, four microbial taxa were identified that fulfilled these requirements, including three 196 taxa (family Alcaligenaceae, genus Sutterella, and order Bacillales) being associated with PC 197 in the UK Biobank cohort, and one taxon (genus Enterohabdus) being associated with PC in 198 Japan Biobank cohort (as shown in **Table 1** and **2**). Meanwhile, the IVW, weighted median, 199 Maximum likelihood, and MR PRESSO, all 4 analysis methods produced similar casual estimates for magnitude and direction. In detail, the family Alcaligenaceae (OR = 0.5, 95% CI 200 201 = 0.29-0.86, p = 0.011, IVW) had a protective effect on PC in European populations, while genus Sutterella (OR = 2.25, 95% CI = 1.27-3.99, p = 0.005, IVW) and order Bacillales (OR = 202 203 1.60, 95% CI = 1.18-2.16, p = 0.002, IVW) were associated with a higher risk of PC. The 204 findings from the Japanese cohort indicated a heightened likelihood of developing PC

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

correlated with the presence of the genus Enterohabdus (OR = 2.38, 95% CI = 1.40-4.04, p =0.001, IVW). **Sensitivity Analyses** The Cochran's Q statistics for all 17 significant risk factors of gut microbiota in PC showed no significant heterogeneity (p > 0.05) (Supplementary Table S2). Meanwhile, no evidence of horizontal pleiotropy for gut microbiota in PC with p > 0.05 was demonstrated by the MR-Egger regression intercept approach (Supplementary Table S3). The heterogeneity of 17 significant risk factors of PC was also revealed by the MR-PRESSO global test, and the analysis revealed no outliers in the results (Supplementary Table S4). Moreover, leave-oneout analysis exhibited no significant difference in causal estimations of all 17 bacterial genera on PC (Supplementary Figure S3 and S4). No association between Pancreatic cancer and the following taxonomic groups was observed in the reverse MR analysis of the UK Biobank data: class Bacyeroidia, family Alcaligenaceae, family Veillonellacease, genus Bilophila, genus Eggerthella, genus LachnospiraceaeUCG004, genus LachnospiraceaeUCG010, genus Parasutterella, guens Sutterella, order Bacillales, and order Bacteroidales (Table 3). As there were few IVs identified from the Japanese Biobank, only 7 IVs were selected even when the cut-off p-value was set as  $1 \times 10^{-5}$ . Therefore, we could not perform reserve MR analysis between PC and the gut microbiome in the population from Eastern Asia. Detailed information on the IVs (P value <  $5x10^{-6}$ ) used in the reverse MR analyses was shown in Supplementary Table S5. Discussion Our study used MR analysis to offer valuable insights into the potential causal relationship between gut microbiota and PC. IVW estimates suggested that within the European population, class Bacteroidia, family Alcaligenaceae, genus Eggerthella, genus LachnospiraceaeUCG004, genus Parasutterella, order Bacteroidales were related to the reduced risk of PC, while family Veillonellaceae, genus Bilophila, genus Lanchnospiraceae UCG010, genus Sutterella, and order Bacillales were positively related to the risk of PC. In the East Asian population, several gut microbiota members were identified to be related to the reduced risk of PC, including family *Christensenellaceae*, genus *Ruminococcusquavus* group, genus Ruminococcus 1, and order Burkholderiales, while the level of class Actinobacteria and genus Enterorhabdus were positively related to the PC. These findings

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

not only contribute to the advancement of our knowledge of microbiota in the development of cancer, but also highlight the importance of ethnicity in the risk of PC. Based on the PC GWAS database from the UK biobank and the Japan biobank, our study indicated that the PC-associated gut microbiome displayed widespread regional differences. Furthermore, a recent meta-analysis conducted on the Finnish biobank data identified a distinct group of bacteria associated with PC. However, these findings varied from the results obtained from biobanks in the UK and Japan. [29, 30]. All this evidence suggested that the PC-related gut microbiota signatures varied across different populations. Previous studies demonstrated strong associations between race (European, African, Asian) and different genera abundances in most cancer types [31]. The incidence of PC is greater in Europe than in East Asia [32]. The disparity may be associated with gut microbiome differences. However, the microbiome profiles among various racial groups in PC, are not well understood. The different abundant bacteria might be attributed to various dietary patterns among individuals from distinct regions. It is noteworthy that the diversity in human gut microbiome composition between ethnic groups manifests as early as three months after birth [33]. Hence, diverse geographic populations should be considered in the microbiotabased disease models [34]. The identification of unique gut microbiota linked to PC in the UK and Japan provide an opportunity to further conduct country-specific studies on the development of PC. The findings generated from our MR analysis were consistent with the previously published results obtained from 16s rRNA sequencing of microbiota in PC patients. The clinical PC faecal microbial profile by 16s rRNA sequencing reported that Eggerthella and Parasutterella were significantly decreased in PC patients compared with healthy control [35]. Another faecal microbiome signature in PC patients was characterised by a decreased presence of bacterial families commonly in the healthy gut, namely Ruminococcaceae and Lachnospiraceae; and an increased presence of Veillonellaceae [36]. Additionally, a comparison of the relative abundances of each microbial species revealed that Sutterella Wadsworthensis and Bilophila were significantly enriched, while Bacteroildes Rodentium was significantly decreased in PC as compared with healthy controls [37, 38]. Thus, the twosample Mendelian randomization study is thought to provide a convincing approach for evaluating the relationships between gut microbiota and PC, as it is compatible with faecal 16s sequencing results.

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

According to our findings, a decrease in the abundance of *Lachnospiraceae* and Ruminococcaceae, as well as an increase in Veillonellaceae, were associated with the PC risk. Strikingly, a similar profile of altered gut microbiota was also exhibited in the patients diagnosed with cirrhosis [39, 40]. In a linkage study in southern England, elevated risks of PC were identified to be related to earlier liver diseases, such as alcoholic cirrhosis, primary biliary cirrhosis and unspecified cirrhosis [41]. Combined with our results, new research will be proposed that a potential role of altered gut flora in cirrhosis patients could contribute to the increased susceptibility to PC. Besides, it is well acknowledged that obesity substantially elevates the risk of PC; however, the underlying mechanisms connecting the two remain poorly understood [42]. The genus Eggerthella, as a protective factor for PC, exhibited a significantly lower abundance in obese individuals compared to non-obese ones [43]. Conversely, the genus *Sutterella* as a risk factor for PC, exhibited an increase in obese people [44, 45]. Given the similarity of the microbiota profiles between the obese population and PC patients, it is reasonable to assume that the microbiota alteration, such as the metabolic changes linked to the Eggerthella and Sutterella [46], could mediate the mechanism by which the obesity initiates the development of PC. Taken together, our study can provide novel insights into the relationships between PC, the microbiome and other risk factors, which could enhance our knowledge of PC development. The therapeutic techniques aiming at the cancer-associated microbiome have been conducted in clinical trials. In this context, our study found that Ruminococcus and Lachnospiraceae were severed as the protective role of PC, suggesting novel and potential treatment targets for gut microbiome-based therapy. Hester et al. [47] demonstrated that the consumption of a substantial quantity of dietary fibre led to the production of a significant level of butyrate production by several bacterial family, such as Lachnospiraceae and Ruminococcaceae, which had preventive properties against the development of colon cancer. The utilization of probiotics in healthy individuals has been found to inhibit the development of colon carcinoma by increasing the number of Ruminococcus species and Clostridiales bacteria [48, 49]. Therefore, the use of probiotics containing Ruminococcus could have promise as a novel therapeutic approach for mitigating the onset of PC. On the other hand, based on our findings, other PC-associated microbiota are worthy of further investigation, making this a promising direction for targeted gut microbiome-based therapy for PC.

300 Our study has several limitations. First, our research included a total of 119 microbial taxa;

however, we did not investigate potential causal associations at the species level. Second,

MR analysis is a computer-based correlation analysis between gut microbiota and PC,

without explaining the underlying process. It would be advantageous to validate the

outcomes via functional experiments. Third, the present study included people of European

and East Asian descent, perhaps restricting the generalizability of the findings to other

306 populations.

301

302

303

304

305

310

311

313

307 In conclusion, this study identified several candidate bacteria that have potential association

308 with PC. Variations in the PC-associated gut microbiota signatures are evidenced with

309 geographical location, which may explain the disparity of PC incidence across nations. The

identification of PC-associated gut microbiota provides the foundation for the exploration of

novel microbiota-targeted therapy for PC. Further studies are needed to better characterise

the potential role of these gut microbiota in the pathogenic mechanisms of PC.

### Reference

- Siegel, R.L., K.D. Miller, and A. Jemal, *Cancer statistics, 2020.* CA Cancer J Clin, 2020.
   **70**(1): p. 7-30.
- Siegel, R.L., K.D. Miller, H.E. Fuchs, and A. Jemal, *Cancer statistics, 2022.* CA Cancer J
   Clin, 2022. **72**(1): p. 7-33.
- 318 3. Huang, B.Z., L. Liu, J. Zhang, U.S.C.P.R. Team, S.J. Pandol, S.R. Grossman, and V.W.
  319 Setiawan, *Rising Incidence and Racial Disparities of Early-Onset Pancreatic Cancer in the United States*, 1995-2018. Gastroenterology, 2022. **163**(1): p. 310-312 e1.
- Khalaf, N., H.B. El-Serag, H.R. Abrams, and A.P. Thrift, *Burden of Pancreatic Cancer:* From Epidemiology to Practice. Clin Gastroenterol Hepatol, 2021. 19(5): p. 876-884.
- Thomas, R.M. and C. Jobin, *Microbiota in pancreatic health and disease: the next frontier in microbiome research.* Nat Rev Gastroenterol Hepatol, 2020. 17(1): p. 53-64.
- Fritz, S., T. Hackert, W. Hartwig, F. Rossmanith, O. Strobel, L. Schneider, K. Will-Schweiger, M. Kommerell, M.W. Buchler, and J. Werner, *Bacterial translocation and infected pancreatic necrosis in acute necrotizing pancreatitis derives from small bowel rather than from colon.* Am J Surg, 2010. **200**(1): p. 111-7.
- Pushalkar, S., M. Hundeyin, D. Daley, C.P. Zambirinis, E. Kurz, A. Mishra, N. Mohan, B.
   Aykut, M. Usyk, L.E. Torres, G. Werba, K. Zhang, Y. Guo, Q. Li, N. Akkad, S. Lall, B.
   Wadowski, J. Gutierrez, J.A. Kochen Rossi, J.W. Herzog, B. Diskin, A. Torres Hernandez, J. Leinwand, W. Wang, P.S. Taunk, S. Savadkar, M. Janal, A. Saxena, X. Li,
- D. Cohen, R.B. Sartor, D. Saxena, and G. Miller, *The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression.*
- 336 Cancer Discov, 2018. **8**(4): p. 403-416.
- 337 8. Aykut, B., S. Pushalkar, R. Chen, Q. Li, R. Abengozar, J.I. Kim, S.A. Shadaloey, D. Wu, P. Preiss, N. Verma, Y. Guo, A. Saxena, M. Vardhan, B. Diskin, W. Wang, J. Leinwand, E.

- Kurz, J.A. Kochen Rossi, M. Hundeyin, C. Zambrinis, X. Li, D. Saxena, and G. Miller, *The* fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature, 2019. **574**(7777): p. 264-267.
- Wei, M.Y., S. Shi, C. Liang, Q.C. Meng, J. Hua, Y.Y. Zhang, J. Liu, B. Zhang, J. Xu, and X.J.
   Yu, The microbiota and microbiome in pancreatic cancer: more influential than
   expected. Mol Cancer, 2019. 18(1): p. 97.
- Fan, X., A.V. Alekseyenko, J. Wu, B.A. Peters, E.J. Jacobs, S.M. Gapstur, M.P. Purdue,
   C.C. Abnet, R. Stolzenberg-Solomon, G. Miller, J. Ravel, R.B. Hayes, and J. Ahn, *Human* oral microbiome and prospective risk for pancreatic cancer: a population-based
   nested case-control study. Gut, 2018. 67(1): p. 120-127.
- Sethi, V., S. Kurtom, M. Tarique, S. Lavania, Z. Malchiodi, L. Hellmund, L. Zhang, U.
   Sharma, B. Giri, B. Garg, A. Ferrantella, S.M. Vickers, S. Banerjee, R. Dawra, S. Roy, S.
   Ramakrishnan, A. Saluja, and V. Dudeja, *Gut Microbiota Promotes Tumor Growth in Mice by Modulating Immune Response*. Gastroenterology, 2018. 155(1): p. 33-37 e6.
- Lee, A.A., Q.L. Wang, J. Kim, A. Babic, X. Zhang, K. Perez, K. Ng, J. Nowak, N. Rifai,
   H.D. Sesso, J.E. Buring, G.L. Anderson, J. Wactawski-Wende, R. Wallace, J.E. Manson,
   E.L. Giovannucci, M.J. Stampfer, P. Kraft, C.S. Fuchs, C. Yuan, and B.M. Wolpin,
   Helicobacter pylori Seropositivity, ABO Blood Type, and Pancreatic Cancer Risk From 5
   Prospective Cohorts. Clin Transl Gastroenterol, 2023. 14(5): p. e00573.
- Yuan, M., Y. Xu, and Z. Guo, Association of oral microbiome and pancreatic cancer: a
   systematic review and meta-analysis. Therap Adv Gastroenterol, 2022. 15: p.
   17562848221123980.
- 361 14. Fewell, Z., G. Davey Smith, and J.A. Sterne, *The impact of residual and unmeasured* 362 *confounding in epidemiologic studies: a simulation study.* Am J Epidemiol, 2007.
   363 166(6): p. 646-55.
- 364 15. Smith, G.D. and A.N. Phillips, *Confounding in epidemiological studies: why*365 "independent" effects may not be all they seem. BMJ, 1992. **305**(6856): p. 757-9.
- 366 16. Phillips, A.N. and G.D. Smith, How independent are "independent" effects? Relative
   367 risk estimation when correlated exposures are measured imprecisely. J Clin
   368 Epidemiol, 1991. 44(11): p. 1223-31.
- 369 17. Richmond, R.C. and G. Davey Smith, *Mendelian Randomization: Concepts and Scope.*370 Cold Spring Harb Perspect Med, 2022. **12**(1).
- Yarmolinsky, J., K.H. Wade, R.C. Richmond, R.J. Langdon, C.J. Bull, K.M. Tilling, C.L.
   Relton, S.J. Lewis, G. Davey Smith, and R.M. Martin, *Causal Inference in Cancer Epidemiology: What Is the Role of Mendelian Randomization?* Cancer Epidemiol
- 374 Biomarkers Prev, 2018. **27**(9): p. 995-1010.
- 375 19. Burgess, S. and S.G. Thompson, *Multivariable Mendelian randomization: the use of*376 pleiotropic genetic variants to estimate causal effects. Am J Epidemiol, 2015. **181**(4):
  377 p. 251-60.
- 378 20. Ma, J., J. Li, C. Jin, J. Yang, C. Zheng, K. Chen, Y. Xie, Y. Yang, Z. Bo, J. Wang, Q. Su, J.
   379 Wang, G. Chen, and Y. Wang, Association of gut microbiome and primary liver cancer:
   380 A two-sample Mendelian randomization and case-control study. Liver Int, 2023.
- **43**(1): p. 221-233.
- 382 21. Ni, J.J., X.S. Li, H. Zhang, Q. Xu, X.T. Wei, G.J. Feng, M. Zhao, Z.J. Zhang, L. Zhang, G.H.
- Shen, and B. Li, *Mendelian randomization study of causal link from gut microbiota to colorectal cancer.* BMC Cancer, 2022. **22**(1): p. 1371.

- Zhou, H., J. Liu, J. Shen, W. Fang, and L. Zhang, *Gut Microbiota and Lung Cancer: A Mendelian Randomization Study.* JTO Clin Res Rep, 2020. 1(3): p. 100042.
- 387 23. Kurilshikov, A., C. Medina-Gomez, R. Bacigalupe, D. Radjabzadeh, J. Wang, A.
- Demirkan, C.I. Le Roy, J.A. Raygoza Garay, C.T. Finnicum, X. Liu, D.V. Zhernakova, M.J.
- Bonder, T.H. Hansen, F. Frost, M.C. Ruhlemann, W. Turpin, J.Y. Moon, H.N. Kim, K. Lull,
- 390 E. Barkan, S.A. Shah, M. Fornage, J. Szopinska-Tokov, Z.D. Wallen, D. Borisevich, L.
- 391 Agreus, A. Andreasson, C. Bang, L. Bedrani, J.T. Bell, H. Bisgaard, M. Boehnke, D.I.
- Boomsma, R.D. Burk, A. Claringbould, K. Croitoru, G.E. Davies, C.M. van Duijn, L.
- Duijts, G. Falony, J. Fu, A. van der Graaf, T. Hansen, G. Homuth, D.A. Hughes, R.G.
- 394 Ijzerman, M.A. Jackson, V.W.V. Jaddoe, M. Joossens, T. Jorgensen, D. Keszthelyi, R.
- 395 Knight, M. Laakso, M. Laudes, L.J. Launer, W. Lieb, A.J. Lusis, A.A.M. Masclee, H.A.
- 396 Moll, Z. Mujagic, Q. Qibin, D. Rothschild, H. Shin, S.J. Sorensen, C.J. Steves, J. Thorsen,
- 397 N.J. Timpson, R.Y. Tito, S. Vieira-Silva, U. Volker, H. Volzke, U. Vosa, K.H. Wade, S.
- Walter, K. Watanabe, S. Weiss, F.U. Weiss, O. Weissbrod, H.J. Westra, G. Willemsen,
- 399 H. Payami, D. Jonkers, A. Arias Vasquez, E.J.C. de Geus, K.A. Meyer, J. Stokholm, E.
- 400 Segal, E. Org, C. Wijmenga, H.L. Kim, R.C. Kaplan, T.D. Spector, A.G. Uitterlinden, F.
- 401 Rivadeneira, A. Franke, M.M. Lerch, L. Franke, S. Sanna, M. D'Amato, O. Pedersen,
- 402 A.D. Paterson, R. Kraaij, J. Raes and A. Zhernakova, *Large-scale association analyses*
- identify host factors influencing human gut microbiome composition. Nat Genet, 2021. **53**(2): p. 156-165.
- 405 24. Sanna, S., N.R. van Zuydam, A. Mahajan, A. Kurilshikov, A. Vich Vila, U. Vosa, Z.
- 406 Mujagic, A.A.M. Masclee, D. Jonkers, M. Oosting, L.A.B. Joosten, M.G. Netea, L.
- 407 Franke, A. Zhernakova, J. Fu, C. Wijmenga, and M.I. McCarthy, *Causal relationships*
- 408 among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat 409 Genet, 2019. **51**(4): p. 600-605.
- 410 25. Burgess, S., A. Butterworth, and S.G. Thompson, *Mendelian randomization analysis*
- with multiple genetic variants using summarized data. Genet Epidemiol, 2013. 37(7):
  p. 658-65.
- 413 26. Hemani, G., J. Zheng, B. Elsworth, K.H. Wade, V. Haberland, D. Baird, C. Laurin, S.
- Burgess, J. Bowden, R. Langdon, V.Y. Tan, J. Yarmolinsky, H.A. Shihab, N.J. Timpson,
- D.M. Evans, C. Relton, R.M. Martin, G. Davey Smith, T.R. Gaunt, and P.C. Haycock, *The*
- 416 MR-Base platform supports systematic causal inference across the human phenome.
- 417 Elife, 2018. **7**.
- 418 27. Verbanck, M., C.Y. Chen, B. Neale, and R. Do, Detection of widespread horizontal
- 419 pleiotropy in causal relationships inferred from Mendelian randomization between
- 420 *complex traits and diseases.* Nat Genet, 2018. **50**(5): p. 693-698.
- 421 28. Bowden, J., M.F. Del Greco, C. Minelli, G. Davey Smith, N. Sheehan, and J. Thompson,
- 422 A framework for the investigation of pleiotropy in two-sample summary data
- 423 *Mendelian randomization.* Stat Med, 2017. **36**(11): p. 1783-1802.
- 424 29. Jiang, Z., Y. Mou, H. Wang, L. Li, T. Jin, H. Wang, M. Liu, and W. Jin, Causal effect
- between gut microbiota and pancreatic cancer: a two-sample Mendelian
- 426 randomization study. BMC Cancer, 2023. **23**(1): p. 1091.
- 427 30. Zhu, S.J. and Z. Ding, Association between gut microbiota and seven gastrointestinal
- 428 diseases: A Mendelian randomized study. J Gene Med, 2023: p. e3623.
- 429 31. Luo, M., Y. Liu, L.C. Hermida, E.M. Gertz, Z. Zhang, Q. Li, L. Diao, E. Ruppin, and L.
- 430 Han, Race is a key determinant of the human intratumor microbiome. Cancer Cell,
- 431 2022. **40**(9): p. 901-902.

- 432 32. Collaborators, G.B.D.P.C., The global, regional, and national burden of pancreatic
- cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a
- systematic analysis for the Global Burden of Disease Study 2017. Lancet
   Gastroenterol Hepatol, 2019. 4(12): p. 934-947.
- 436 33. Mallott, E.K., A.R. Sitarik, L.D. Leve, C. Cioffi, C.A. Camargo, Jr., K. Hasegawa, and S.R. Bordenstein, *Human microbiome variation associated with race and ethnicity*
- 438 *emerges as early as 3 months of age.* PLoS Biol, 2023. **21**(8): p. e3002230.
- 439 34. He, Y., W. Wu, H.M. Zheng, P. Li, D. McDonald, H.F. Sheng, M.X. Chen, Z.H. Chen, G.Y.
- Ji, Z.D. Zheng, P. Mujagond, X.J. Chen, Z.H. Rong, P. Chen, L.Y. Lyu, X. Wang, C.B. Wu,
- N. Yu, Y.J. Xu, J. Yin, J. Raes, R. Knight, W.J. Ma, and H.W. Zhou, Regional variation
- limits applications of healthy gut microbiome reference ranges and disease models.
- 443 Nat Med, 2018. **24**(10): p. 1532-1535.
- 444 35. Ren, Z., J. Jiang, H. Xie, A. Li, H. Lu, S. Xu, L. Zhou, H. Zhang, G. Cui, X. Chen, Y. Liu, L.
- Wu, N. Qin, R. Sun, W. Wang, L. Li, W. Wang, and S. Zheng, Gut microbial profile
- 446 analysis by MiSeq sequencing of pancreatic carcinoma patients in China. Oncotarget, 447 2017. **8**(56): p. 95176-95191.
- 448 36. Half, E., N. Keren, L. Reshef, T. Dorfman, I. Lachter, Y. Kluger, N. Reshef, H. Knobler, Y.
- 449 Maor, A. Stein, F.M. Konikoff, and U. Gophna, Fecal microbiome signatures of
- 450 pancreatic cancer patients. Sci Rep, 2019. **9**(1): p. 16801.
- 451 37. Nagata, N., S. Nishijima, Y. Kojima, Y. Hisada, K. Imbe, T. Miyoshi-Akiyama, W. Suda,
- M. Kimura, R. Aoki, K. Sekine, M. Ohsugi, K. Miki, T. Osawa, K. Ueki, S. Oka, M.
- 453 Mizokami, E. Kartal, T.S.B. Schmidt, E. Molina-Montes, L. Estudillo, N. Malats, J.
- 454 Trebicka, S. Kersting, M. Langheinrich, P. Bork, N. Uemura, T. Itoi, and T. Kawai,
- 455 Metagenomic Identification of Microbial Signatures Predicting Pancreatic Cancer
- 456 From a Multinational Study. Gastroenterology, 2022. **163**(1): p. 222-238.
- 457 38. Matsukawa, H., N. Iida, K. Kitamura, T. Terashima, J. Seishima, I. Makino, T. Kannon, K.
- Hosomichi, T. Yamashita, Y. Sakai, M. Honda, T. Yamashita, E. Mizukoshi, and S.
- 459 Kaneko, Dysbiotic gut microbiota in pancreatic cancer patients form correlation
- 460 networks with the oral microbiota and prognostic factors. Am J Cancer Res, 2021.
- 461 **11**(6): p. 3163-3175.
- 462 39. Chen, Y., F. Yang, H. Lu, B. Wang, Y. Chen, D. Lei, Y. Wang, B. Zhu, and L. Li,
- 463 Characterization of fecal microbial communities in patients with liver cirrhosis.
- 464 Hepatology, 2011. **54**(2): p. 562-72.
- 465 40. Bajaj, J.S., P.B. Hylemon, J.M. Ridlon, D.M. Heuman, K. Daita, M.B. White, P.
- 466 Monteith, N.A. Noble, M. Sikaroodi, and P.M. Gillevet, *Colonic mucosal microbiome*
- differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to
- *cognition and inflammation.* Am J Physiol Gastrointest Liver Physiol, 2012. **303**(6): p.
- 469 G675-85.
- 470 41. Goldacre, M.J., C.J. Wotton, D. Yeates, V. Seagroatt, and J. Collier, *Liver cirrhosis, other*
- liver diseases, pancreatitis and subsequent cancer: record linkage study. Eur J
- 472 Gastroenterol Hepatol, 2008. **20**(5): p. 384-92.
- 473 42. Li, Z., L. Jin, L. Xia, X. Li, Y. Guan, and H. He, Body mass index, C-reactive protein, and
- 474 pancreatic cancer: A Mendelian randomization analysis to investigate causal
- 475 pathways. Front Oncol, 2023. 13: p. 1042567.
- 476 43. Verdam, F.J., S. Fuentes, C. de Jonge, E.G. Zoetendal, R. Erbil, J.W. Greve, W.A.
- Buurman, W.M. de Vos, and S.S. Rensen, *Human intestinal microbiota composition is*


- associated with local and systemic inflammation in obesity. Obesity (Silver Spring),
   2013. 21(12): p. E607-15.
- 480 44. Oduaran, O.H., F.B. Tamburini, V. Sahibdeen, R. Brewster, F.X. Gomez-Olive, K. Kahn,
  481 S.A. Norris, S.M. Tollman, R. Twine, A.N. Wade, R.G. Wagner, Z. Lombard, A.S. Bhatt,
  482 and S. Hazelhurst, *Gut microbiome profiling of a rural and urban South African cohort*483 reveals biomarkers of a population in lifestyle transition. BMC Microbiol, 2020. **20**(1):
  484 p. 330.
- 485 45. Gao, X., M. Zhang, J. Xue, J. Huang, R. Zhuang, X. Zhou, H. Zhang, Q. Fu, and Y. Hao,
   486 Body Mass Index Differences in the Gut Microbiota Are Gender Specific. Front
   487 Microbiol, 2018. 9: p. 1250.
- 488 46. de Wit, D.F., N.M.J. Hanssen, K. Wortelboer, H. Herrema, E. Rampanelli, and M.
   489 Nieuwdorp, Evidence for the contribution of the gut microbiome to obesity and its
   490 reversal. Sci Transl Med, 2023. 15(723): p. eadg2773.
- 491 47. Hester, C.M., V.R. Jala, M.G. Langille, S. Umar, K.A. Greiner, and B. Haribabu, *Fecal microbes, short chain fatty acids, and colorectal cancer across racial/ethnic groups.*493 World J Gastroenterol, 2015. **21**(9): p. 2759-69.
- 48. Walia, S., R. Kamal, S.S. Kanwar, and D.K. Dhawan, *Cyclooxygenase as a target in chemoprevention by probiotics during 1,2-dimethylhydrazine induced colon carcinogenesis in rats.* Nutr Cancer, 2015. **67**(4): p. 603-11.

49. Zhang, X., Y. Zhao, J. Xu, Z. Xue, M. Zhang, X. Pang, X. Zhang, and L. Zhao, *Modulation*498 of gut microbiota by berberine and metformin during the treatment of high-fat diet499 induced obesity in rats. Sci Rep, 2015. **5**: p. 14405.


## Figure 1

## The study design and the overall workflow.


Assumption 1: the genetic variant is directly associated with the exposure;
Assumption 2: the genetic variant is not related to factors known to obscure the connection between the exposure and the effect;
Assumption 3: the genetic variant has no effect other than through the exposure.



**Table 1**Causal associations of the gut microbiota with pancreatic cancer risk in the European population.




**Table 2**Causal associations of the gut microbiota with pancreatic cancer risk in the East Asian population.



Scatter plot of the association between gut microbiota and pancreatic cancer based on UK biobank database.


(A) class *Bacteroidia*; (B) family *Alcaligenaceae*; (C) family *Veillonellaceae*; (D) genus *Bilophila*; (E) genus *Eggerthella*; (F) genus *LachnospiraceaeUCG004*; (G) genus *LachnospiraceaeUCG010*; (H) genus *Parasutterella*; (I) genus *Sutterella*; (J) order *Bacillales*;



Scatter plot of the association between gut microbiota and pancreatic cancer based on Japan biobank database.

(A) class Actinobacteria; (B) family Christensenellaceae; (C) genus

Rumminococcusgnavusgroup; (D) genus Enterorhabdus; (E) genus Ruminococcus1; (F) ordr Burkhoderiales



617

618

619

620

621 622

623


624 625 626 Leave-one-out sensitivity analysis for the association between genetically predicted gut microbiota and pancreatic cancer based on UK biobank database.

(A) class Bacteroidia; (B) family Alcaligenaceae; (C) family Veillonellaceae; (D) genus

Bilophila; (E) genus Eggerthella; (F) genus LachnospiraceaeUCG004; (G) genus

LachnospiraceaeUCG010; (H) genus Parasutterella; (I) genus Sutterella; (J) order Bacillales;

(K) order Bacteroidales



Leave-one-out sensitivity analysis for the association between genetically predicted gut microbiota and pancreatic cancer based on Japan biobank database.

(A) class Actinobacteria; (B) family Christensenellaceae; (C) genus

Rumminococcusgnavusgroup; (D) genus Enterorhabdus; (E) genus Ruminococcus1; (F) ordr

Burkhoderiales

